E*TRADE Financial Corp (NASDAQ:ETFC) declared its Monthly Activity Report for February 2015. Daily Average Revenue Trades (DARTs) for February were 179,420, a four percent increase from January and an 11 percent decrease from the year-ago period. The Company added 37,224 gross new brokerage accounts in February, ending the month with approximately 3.2 million brokerage accounts — an increase of 20,715 from January.
E*TRADE Financial Corp (NASDAQ:ETFC) rose0.35% and closed at $28.38. The 52-week range for the stock is $18.20 and $28.52 and during the previous trading session the stock touched its highest price at $28.52. Its introductory price for the day was $28.06, with the overall traded volume of 1.98 million shares.
How Should Investors React to ETFC Now? Find Out in this Trend Analysis Report
Costco Wholesale Corporation (NASDAQ:COST) reported that it has entered into a new co-brand credit card program agreement with Citi and an acceptance and co-brand incentive agreement with Visa. The implementation of these agreements is subject to the purchase of the existing co-brand credit card portfolio by Citi. Under the terms of the agreements, Citi, the worlds largest issuer of consumer credit cards, would become the exclusive issuer of Costcos co-brand credit cards and Visa will replace American Express as the credit card network for Costco in the United States and Puerto Rico beginning April 1, 2016.
Costco Wholesale Corporation (NASDAQ:COST) gaining 0.3% and closed at $150.03 on a traded volume of 1.97 million shares, in comparison to 2.89 million shares of average trading volume. The company has a total market capitalization of $ 65.99B.
Get a Free Report and Detailed Analysis on COST Click Here to Read
Biogen Idec Inc (NASDAQ:BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) declared positive top-line results of the Kids B-LONG Phase 3 clinical study that evaluated the safety, efficacy and pharmacokinetics of Alprolix® [Coagulation Factor IX (Recombinant), Fc Fusion Protein] in children under age 12 with severe haemophilia B. Alprolix was generally well tolerated and no inhibitors (neutralising antibodies that may interfere with the activity of the therapy) were detected during the study. In this study, once-weekly prophylactic dosing with Alprolix resulted in low bleeding rates. Alprolix is the only approved hemophilia B therapy with prolonged circulation in the body.
Biogen Idec Inc (NASDAQ:BIIB) surged 1.14% and closed at $426.12 on a traded volume of 1.97 million shares, whereas its average trading volume is 1.44 million shares. The Intra-day range for the stock is $ 417.50 426.48 and Total of 234.56M outstanding shares.
Can BIIB Show a Strong Recovery? Find out in This Research Report
To receive alerts before the crowd, text the word MARKETS to 33733